Xenetic Biosciences Expands Collaboration for Cancer Treatment

Xenetic Biosciences ( (XBIO) ) just unveiled an update.

Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to further develop its DNase oncology platform. This initiative aims to enhance cancer treatment efficacy by targeting neutrophil extracellular traps, which promote cancer progression. The partnership focuses on combining DNase with CAR T-cell therapies, showing promise in preclinical studies for reducing tumor burden and improving therapeutic responses, with plans to advance towards clinical development for pancreatic and other solid tumors.

See more data about XBIO stock on TipRanks’ Stock Analysis page.